The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

With a potential buyer not working out, Idorsia has adjusted an existing partnership and restructured bonds to raise cash.

Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Full Year ...

In a report released on February 26, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...